QHSLab (OTCQB:USAQ) Completes Repurchase of Legacy Debt, Enhancing Capital Structure, Strengthening Balance Sheet and Reducing Future Dilution
LakeShore Biopharma (Nasdaq:LSB) announced that effective September 22, 2025 its ordinary shares and warrants were suspended from trading on Nasdaq and are expected to begin trading on the OTC Pink Open Market under symbols LSBCF (shares) and LSBWF (warrants).
The Nasdaq action follows a delisting determination dated September 11, 2025 due to non-compliance with the minimum bid price rule and ineligibility for a compliance period because of a prior reverse stock split. The company said the transition does not change business operations and that it remains a reporting company with the SEC.
LakeShore Biopharma (Nasdaq:LSB) ha annunciato che, a partire dal 22 settembre 2025, le sue azioni ordinarie e i warrant sono stati sospesi dalla negoziazione su Nasdaq e dovrebbero iniziare a essere negoziati sul OTC Pink Open Market con i simboli LSBCF (azioni) e LSBWF ( warrant).
L'azione Nasdaq segue una decisione di esclusione dalla quotazione datata 11 settembre 2025 a causa del mancato rispetto del requisito minimo di prezzo di offerta e dell'inidoneità a un periodo di conformità a causa di una precedente divisione azionaria inversa. L'azienda ha dichiarato che la transizione non modifica le operazioni aziendali e che rimane una società che presenta rapporti alla SEC.
LakeShore Biopharma (Nasdaq:LSB) anunció que, con efecto el 22 de septiembre de 2025, sus acciones ordinarias y las warrants fueron suspendidas de negociación en Nasdaq y se espera que comiencen a cotizar en el Mercado Abierto Pink OTC bajo los símbolos LSBCF (acciones) y LSBWF (warrants).
La acción de Nasdaq sigue a una determinación de exclusión de cotización con fecha de 11 de septiembre de 2025 debido al incumplimiento de la regla de precio de oferta mínimo e inelegibilidad para un periodo de cumplimiento debido a una previamente realizada división de acciones inversa. La compañía dijo que la transición no modifica las operaciones comerciales y que continúa siendo una compañía que presenta informes ante la SEC.
LakeShore Biopharma (나스닥:LSB)가 2025년 9월 22일부로 보통주와 워런트의 거래가 나스닥에서 중단되었으며, OTC Pink Open Market에서 LSBCF (주식)와 LSBWF (워런트) 심볼로 거래가 시작될 것으로 예상한다고 발표했습니다.
나스닥 조치는 2025년 9월 11일에 작성된 상장폐지 결정에 따라 최소호가 규칙 위반 및 이전의 역분할로 인해 일정 기간의 준수 요건에 해당하지 못한 것 때문이라고 합니다. 회사는 이번 전환이 비즈니스 운영을 변경하지 않으며 여전히 SEC에 보고하는 회사임을 명시했습니다.
LakeShore Biopharma (Nasdaq:LSB) a annoncé que, à compter du 22 septembre 2025, ses actions ordinaires et ses warrants ont été suspendus de la négociation sur Nasdaq et devraient commencer à se négocier sur le OTC Pink Open Market sous les symboles LSBCF (actions) et LSBWF ( warrants).
Cette action de Nasdaq fait suite à une décision de radiation datée du 11 septembre 2025 en raison du non-respect de la règle du prix d’offre minimum et de l’inéligibilité à une période de conformité en raison d’un précédent fractionnement d’actions inversé. La société a déclaré que la transition ne modifie pas les opérations commerciales et qu’elle demeure une entreprise soumise à des rapports auprès de la SEC.
LakeShore Biopharma (Nasdaq:LSB) gab bekannt, dass mit Wirkung vom 22. September 2025 ihre Stammaktien und Warrants vom Handel an der Nasdaq suspendiert wurden und voraussichtlich am OTC Pink Open Market unter den Symbolen LSBCF (Aktien) und LSBWF (Warrants) gehandelt werden.
Die Nasdaq-Maßnahme folgt auf eine Delisting-Entscheidung vom 11. September 2025 aufgrund der Nichteinhaltung der Mindestpreis-Regel und der Nichtberechtigung für eine Compliance-Periode aufgrund einer vorherigen inversen Aktienteilung. Das Unternehmen sagte, die Transition ändere nichts am Geschäftsablauf und dass es weiterhin eine bei der SEC meldende Gesellschaft bleibe.
LakeShore Biopharma (ناسداك:LSB) أعلنت أنه اعتباراً من 22 سبتمبر 2025 سيتم تعليق أسهمها العادية ووَراتها من التداول في Nasdaq ومن المتوقع أن يبدأ التداول في OTC Pink Open Market تحت الرموز LSBCF (الأسهم) وLSBWF (الواتورنتس).
يأتي إجراء ناسداك نتيجة قرار الإيقاف المؤرخ في 11 سبتمبر 2025 بسبب عدم الامتثال لقاعدة الحد الأدنى لسعر العرض وعدم الأهلية لفترة امتثال بسبب تقسيم عكسي سابق للأسهم. قالت الشركة إن الانتقال لا يغيّر عمليات الأعمال وأنها تظل شركة تقدم تقارير إلى هيئة الأوراق المالية والبورصات (SEC).
- Remains an active SEC reporting company
- Company says transition does not change operations
- Shares and warrants suspended from Nasdaq effective September 22, 2025
- Delisting determined due to minimum bid non-compliance and ineligibility for a compliance period after a reverse split
On the same day, the Company's ordinary shares and warrants are expected to commence trading on the OTC Pink Open Market ("OTC Market") under the symbols "LSBCF" and "LSBWF", respectively.
This action follows the receipt of a delisting determination letter from Nasdaq on September 11, 2025, as previously disclosed by the Company on September 12, 2025. Nasdaq's determination was based on the Company's non-compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) and its ineligibility for a compliance period under Nasdaq Listing Rule 5810(c)(3)(A)(iv) due to a prior reverse stock split.
The transition to the OTC Market does not change the Company's business operations. The Company remains a reporting company with the
About LakeShore Biopharma
LakeShore Biopharma, previously known as YS Biopharma, is a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA® immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Hepatitis B, Influenza, and other virus infections. The Company operates in
Cautionary Statement Regarding Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical or current fact included in this press release are forward-looking statements, including but not limited to statements regarding the Board's evaluation of the Proposal Letter and the Proposed Transaction. Forward-looking statements may be identified by the use of words such as "estimate," "plan," "project," "potential," "forecast," "intend," "will," "expect," "anticipate," "believe," "goal," "seek," "target" or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These statements are based on various assumptions, whether identified in this press release, and on the current expectations of LakeShore Biopharma's management and are not predictions of actual performance.
LakeShore Biopharma cannot assure you the forward-looking statements in this press release will be accurate. These forward-looking statements are subject to a number of risks and uncertainties, including those included under the heading "Risk Factors" in the Company's Annual Report on Form 20-F filed with the Securities and Exchange Commission, or SEC, and other risks described in documents subsequently filed by the Company from time to time with the SEC. There may be additional risks that LakeShore Biopharma does not presently know or that LakeShore Biopharma currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In light of the significant uncertainties in these forward-looking statements, nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. The forward-looking statements in this press release represent the views of LakeShore Biopharma as of the date of this press release. Subsequent events and developments may cause those views to change. However, while LakeShore Biopharma may update these forward-looking statements in the future, there is no current intention to do so, except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing the views of LakeShore Biopharma as of any date subsequent to the date of this press release. Except as may be required by law, LakeShore Biopharma does not undertake any duty to update these forward-looking statements.
View original content:https://www.prnewswire.com/news-releases/lakeshore-biopharma-announces-transition-to-otc-market-following-nasdaq-delisting-302562861.html
SOURCE LakeShore Biopharma Co., Ltd.
FAQ
Why were LakeShore Biopharma shares suspended from Nasdaq on September 22, 2025 (LSB)?
What symbols will LakeShore Biopharma trade under on the OTC Market?
Does the move to the OTC Pink market change LakeShore Biopharma's business operations?
Is LakeShore Biopharma still a reporting company after leaving Nasdaq?
What triggered Nasdaq's delisting determination for LakeShore Biopharma (LSB)?
